Literature DB >> 10459276

Risperidone as an adjunct therapy for post-traumatic stress disorder.

D Krashin1, E W Oates.   

Abstract

Risperidone, an atypical antipsychotic medication, has gained wide acceptance as a first-line drug for several indications. Recently, interest has arisen in the use of risperidone as an adjunct therapy in post-traumatic stress disorder (PTSD). PTSD is a possible sequela of exposure to traumatic events. The military population, because of occupational exposure, is at a higher risk than the general population to develop PTSD, and the treatment of PTSD may be a significant issue for military practitioners. PTSD may be complicated by social issues and comorbid psychiatric conditions, and it is often difficult to treat. We present two case reports on the use of risperidone in the treatment of the intrusive thoughts and subsequent emotional reactivity experienced by some PTSD patients, along with a discussion of some possible mechanisms of action for the efficacy of risperidone in the treatment of these symptoms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10459276

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  6 in total

1.  Pharmacotherapy of treatment-resistant combat-related posttraumatic stress disorder with psychotic features.

Authors:  Nela Pivac; Dragica Kozarić-Kovacić
Journal:  Croat Med J       Date:  2006-06       Impact factor: 1.351

2.  Ziprasidone therapy for post-traumatic stress disorder.

Authors:  Zakaria Siddiqui; William A Marcil; Subhash C Bhatia; Sriram Ramaswamy; Frederick Petty
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

3.  Use of antipsychotics in the treatment of post-traumatic stress disorder.

Authors:  Babatunde Adetunji; Maju Mathews; Adedapo Williams; Kumar Budur; Manu Mathews; Jamal Mahmud; Thomas Osinowo
Journal:  Psychiatry (Edgmont)       Date:  2005-04

4.  Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder.

Authors:  Nela Pivac; Dragica Kozaric-Kovacic; Dorotea Muck-Seler
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

5.  Psychopharmacotherapy of posttraumatic stress disorder.

Authors:  Dragica Kozaric-Kovacic
Journal:  Croat Med J       Date:  2008-08       Impact factor: 1.351

6.  Off-label indications for atypical antipsychotics: A systematic review.

Authors:  Konstantinos N Fountoulakis; Ioannis Nimatoudis; Apostolos Iacovides; George Kaprinis
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-02-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.